Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pomalidomide
Find trials that include:  Any drugs shown
Results 1-23 of 23 for your search:
Start Over
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-4047-MM-007, NCI-2013-00024, NCT01734928
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AMyC 10-MM-01, NCI-2012-01279, IST-CAR-521, PO-MM-PI-0034, NCT01464034
Pomalidomide in Treating Patients with Kaposi Sarcoma with or without HIV
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0047, NCI-2013-01525, 120047, P11847, PO-KS-NCI-0050, NCT01495598
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1088, NCI-2012-01168, MMRC# 044, NCT01665794
Bendamustine Hydrochloride, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00040206, NCI-2013-00480, MM-PI-0045, PO-MM-PI-0045, NCT01754402
Pomalidomide, Dexamethasone, and Filgrastim in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0018, NCI-2014-01270, NCI-2014-00159, NCT01946152
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-MM-102, NCI-2014-00978, NCT01997840
Pomalidomide and Dexamethasone with or without Ixazomib in Treating Patients with Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A061202, NCI-2013-01702, CALGB-A061202, NCT02004275
Ixazomib plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12267, NCI-2014-00803, 116980, NCT02119468
Pomalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1011007607, NCI-2012-00192, NCT01319422
Pomalidomide in Treating Patients with Chronic Graft-Versus-Host Disease
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 to 75
Trial IDs: 12-C-0197, NCI-2013-01552, 120197, P12974, NCT01688466
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiply Myeloma and Impaired Renal Function (POM Renal)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC-4047-MM-008, NCI-2012-00966, NCT01575925
Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1281, NCI-2012-01948, Mod12-003419-17, NCT01722305
Everolimus, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: INST 1304, NCI-2014-01538, 14-129, NCI-2014-01186, NCT01889420
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR103015, NCI-2014-02217, 2013-003491-12, 54767414MMY1001, NCT01998971
Pomalidomide after Combination Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: J13128, NCI-2013-02426, MD017, NA_00089739, 9524, NCT02029950
Combination Study of Pomalidomide, Marizomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NPI-0052-107, NCI-2014-01057, NCT02103335
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-MM-104, NCI-2014-01879, NCT02189343
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TCD14079, NCI-2015-00804, U1111-1155-7484, NCT02283775
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-MM-200, NCI-2015-00778, NCT02400242
Pomalidomide in Treating Younger Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 20
Trial IDs: PBTC-043, NCI-2014-02182, CC-4047-PBTC-043, PPBTC-043_R04PAPP01, NCT02415153
Start Over